Search results for "KINASE"

showing 10 items of 2635 documents

Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 pati…

2007

<i>Objective:</i> We aimed to investigate the existence of associations between well-established and newly recognized biological and phenotypic features of breast cancer involved in tumor progression and prognosis. <i>Methods:</i> Ninety-eight cases of invasive breast cancer were assessed for the immunohistochemical expression of estrogen and progesterone receptors, Ki-67, HER2, Akt-1, and Notch-2, using the tissue microarray technique. Data regarding tumor histotype, histological grade, tumor size and lymph node status were collected for each patient and included in the analysis. <i>Results:</i> Several significant associations between histological and/o…

AdultOncologyCA15-3medicine.medical_specialtybreast cancer immunophenotypic analysis Notch-2 Akt-1 HER2/neuReceptor ErbB-2Breast NeoplasmsSettore MED/08 - Anatomia PatologicaHER2/neuImmunophenotypingPathology and Forensic MedicineBreast cancerImmunophenotypingInternal medicineBiomarkers TumormedicineHumansReceptor Notch2Notch 2Molecular BiologyProtein kinase BAgedAged 80 and overTissue microarraybiologybusiness.industryCancerCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseReceptors EstrogenTissue Array Analysisbiology.proteinFemaleReceptors ProgesteronebusinessProto-Oncogene Proteins c-akt
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome

2006

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a life-threatening condition associated with ovarian stimulation. Its pathophysiology is unknown and its treatment continues to be empirical. Early (E)- and late (L)-OHSS occur in women at risk, though not in all cases. Vascular endothelial growth factor (VEGF) is related to increased vascular permeability in OHSS. We analysed the dynamics of the VEGF system in E- and L-OHSS. METHODS A prospective cohort of women undergoing IVF-ICSI treatment were divided into groups. E-OHSS: Nonpregnant patients classified as women not at risk (group 1) (n = 11) and patients at risk who did not (group 2) (n = 18) and did (group 3) (n = 8) develop sever…

AdultOvulationVascular Endothelial Growth Factor Amedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectOvarian hyperstimulation syndromeVascular permeabilityOvaryFertilization in VitroBiologyCohort StudiesOvarian Hyperstimulation Syndromechemistry.chemical_compoundInternal medicineBlood plasmamedicineHumansalpha-MacroglobulinsSperm Injections IntracytoplasmicProspective cohort studyOvulationmedia_commonVascular Endothelial Growth Factor Receptor-1OvaryRehabilitationObstetrics and Gynecologymedicine.diseaseVascular endothelial growth factorEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryOocytesFemaleSoluble fms-like tyrosine kinase-1Human Reproduction
researchProduct

A Novel Loss-of-Function Mutation (N48K) in the PTEN Gene in a Spanish Patient with Cowden Disease

2003

Cowden disease, also known as multiple hamartoma syndrome, is a rare disease inherited in an autosomal dominant pattern, which confers a high risk of developing breast and thyroid carcinomas. Mutations in PTEN, a tumor suppressor gene located on chromosome 10q23, have been identified in patients with Cowden disease. In this work, the direct sequencing of all coding regions of the PTEN gene led us to the identification of N48K, a new germline PTEN missense mutation, in a patient suffering from Cowden disease. The genetic analysis of 200 chromosomes from healthy individuals revealed that the variant was not common in our population. Moreover, by functional analysis we found that the ability o…

AdultPTENcongenital hereditary and neonatal diseases and abnormalitiesTumor suppressor geneDNA Mutational AnalysisMolecular Sequence DataLoss of Heterozygositygenetic analysisDermatologyProtein Serine-Threonine Kinasesmedicine.disease_causeProto-Oncogene MasBiochemistryGenètica molecularfunctional analysisLoss of heterozygosityStructure-Activity RelationshipProto-Oncogene ProteinsmedicineLeukocytesMissense mutationPTENHumansPoint MutationCowden diseaseAmino Acid SequenceMolecular BiologyTumorsGeneticsMutationbiologySequence Homology Amino AcidPoint mutationTumor Suppressor ProteinsPTEN PhosphohydrolaseMultiple hamartoma syndromeCowden syndromeCell Biologymedicine.diseasePhosphoric Monoester HydrolasesN48KSpainbiology.proteinCancer researchFemaleHamartoma Syndrome MultipleProto-Oncogene Proteins c-akt
researchProduct

New adenylate kinase 7 (AK7) mutation in primary ciliary dyskinesia.

2012

Background Primary ciliary dyskinesia (PCD) is a congenital hereditary disease affecting 1/20,000–60,000 people that causes chronic sinusitis, bronchiectasis, sinus hypoplasia, secretory otitis media, and low fertility. The complexity and heterogeneity of the disease make diagnosis difficult. Although the genetic origin of PCD is clear, mutations in only five genes have been associated with the disease, and, to date, no disease-causing gene has been identified. Recently, low levels of AK7 gene expression have been linked to PCD. This study was designed to determine the mutational status of the AK7 gene in 31 PCD (17 PCD and 14 Kartagener syndrome diagnosed) patients compared with 40 healthy…

AdultPathologymedicine.medical_specialtySingle-nucleotide polymorphismBiologyReal-Time Polymerase Chain ReactionPolymorphism Single NucleotideExonCiliogenesisGene expressionotorhinolaryngologic diseasesmedicineImmunology and AllergyHumansChildGenePrimary ciliary dyskinesiaKartagener SyndromeAdenylate KinaseKartagener SyndromeGeneral MedicineMiddle Agedmedicine.diseaseReal-time polymerase chain reactionOtorhinolaryngologyMutationAmerican journal of rhinologyallergy
researchProduct

Myocardial and Peripheral Lymphocytic Transcriptomic Dissociation of β-adrenoceptors and G Protein–coupled Receptor Kinases in Heart Transplantation

2009

Background The genetic expression of adrenergic receptors plays an important pathophysiologic role in heart failure. G protein–coupled receptor kinases (GRKs) desensitize the β-receptor to catecholaminergic stimulation. It has been suggested that their mRNA expression in peripheral lymphocytes could mirror the changes in their myocardial expression in the failing heart, but this relationship between the myocyte and lymphocyte has not been studied in heart transplantation (HT). The objective of this study was to analyze adrenergic receptor and GRK mRNA expression in myocardium and lymphocytes and their correlation. Methods Twenty-three HT patients without evidence of acute rejection or echoc…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdrenergic receptorBiopsymedicine.medical_treatmentLymphocyteInternal medicineReceptors Adrenergic betamedicineHumansLymphocytesRNA MessengerReceptorHeart transplantationTransplantationG protein-coupled receptor kinasebiologybusiness.industryGene Expression ProfilingMyocardiumBeta adrenergic receptor kinaseHeartMiddle AgedG-Protein-Coupled Receptor Kinasesmedicine.diseaseTransplantationEndocrinologymedicine.anatomical_structureHeart failurebiology.proteinHeart TransplantationSurgeryReceptors Adrenergic beta-2Receptors Adrenergic beta-1Cardiology and Cardiovascular MedicinebusinessThe Journal of Heart and Lung Transplantation
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

Pleural Mesothelial Cells Express Both BLT2 and PPARα and Mount an Integrated Response to Pleural Leukotriene B4

2008

Abstract Leukotriene B4 (LTB4) plays a crucial role in the recruitment of neutrophils into the pleural space. We identified for the first time the mechanisms by which LTB4 interacts with mesothelial cells and recruits neutrophils in the pleural compartment. Primary pleural mesothelial cells express both the proinflammatory receptor for LTB4 BLT2, and the anti-inflammatory receptor for LTB4, PPARα. Parapneumonic pleural effusions highly increase BLT2 expression and, via BLT2 activation, increase the adhesion between mesothelial cells and neutrophils and the expression of ICAM-1 on mesothelial cells. The block of PPARα further increases both cell adhesion and ICAM-1 expression. BLT2 activatio…

Adultmedicine.drug_classLeukotriene B4Blotting WesternImmunologyReceptors Leukotriene B4Protein tyrosine phosphataseBiologyLeukotriene B4EpitheliumTyrosine-kinase inhibitorProinflammatory cytokinechemistry.chemical_compoundCell AdhesionmedicineHumansImmunology and AllergyPPAR alphaCell adhesionCells CulturedAgedInflammationLeukotriene B4 receptorPneumoniaMiddle Agedrespiratory systemFlow CytometryIntercellular Adhesion Molecule-1respiratory tract diseasesPleural EffusionChemotaxis LeukocyteNeutrophil InfiltrationchemistryImmunologyCancer researchPleuraPhosphorylationMesothelial CellThe Journal of Immunology
researchProduct

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct